Biological evaluation of novel benzisoxazole derivatives as PPARdelta agonists.
Article Details
- CitationCopy to clipboard
Sakuma S, Endo T, Kanda T, Nakamura H, Yamasaki S, Yamakawa T
Biological evaluation of novel benzisoxazole derivatives as PPARdelta agonists.
Bioorg Med Chem. 2011 May 15;19(10):3255-64. doi: 10.1016/j.bmc.2011.03.053. Epub 2011 Mar 31.
- PubMed ID
- 21515063 [ View in PubMed]
- Abstract
We discovered novel peroxisome proliferator-activated receptor delta agonists with a characteristic benzisoxazole ring. Compound 5 exhibited potent human PPARdelta transactivation activity. Furthermore, it stimulated the differentiation of oligodendrocyte precursor cells in vitro. This indicates that this potential drug may be effective for the treatment of demyelinating disorders such as multiple sclerosis.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Cardarine Peroxisome proliferator-activated receptor alpha EC 50 (nM) 990 N/A N/A Details Cardarine Peroxisome proliferator-activated receptor delta EC 50 (nM) 1.7 N/A N/A Details GW-590735 Peroxisome proliferator-activated receptor alpha EC 50 (nM) 10 N/A N/A Details Rosiglitazone Peroxisome proliferator-activated receptor alpha EC 50 (nM) >10000 N/A N/A Details Rosiglitazone Peroxisome proliferator-activated receptor delta EC 50 (nM) >10000 N/A N/A Details Rosiglitazone Peroxisome proliferator-activated receptor gamma EC 50 (nM) 100 N/A N/A Details